A Study of FG-3246 in Participants With Metastatic Castration-Resistant Prostate Cancer (mCRPC)

The purpose of this study is to evaluate the safety, efficacy, tolerability, and pharmacokinetics (PK) of FG-3246, a cluster of differentiation 46 (CD46) targeting antibody-drug conjugate (ADC), in the treatment of participants with mCRPC who have progressed following treatment with one prior second-generation androgen receptor signaling inhibitor (ARSI) in any setting and no prior taxane therapy in the mCRPC setting.

Trial Details

NCT ID

NCT06842498

Phase

PHASE2

Sponsor

Kyntra Bio

Status

RECRUITING

Cancer Type

Castration-Resistant (CRPC) Prostate Cancer

Interventions

FG-3246

Locations (sample)

Goodyear, Arizona, United States|33.43532,-112.35821
Scottsdale, Arizona, United States|33.50921,-111.89903
Tucson, Arizona, United States|32.22174,-110.92648
Los Angeles, California, United States|34.05223,-118.24368
Los Angeles, California, United States|34.05223,-118.24368

Key Eligibility Criteria

Participant must have histological, and/or cytological confirmation of prostate adenocarcinoma on all prior tumor biopsies.
Participant with soft tissue disease and a safely accessible soft tissue tumor lesion(s) must agree to biopsy of a primary or metastatic lesion dur…
Participant must have serum testosterone levels \<50 nanograms (ng)/deciliter (dL) during screening.
Participant is required to have progressed on no more than one prior treatment with a second generation ARSI (abiraterone acetate, enzalutamide, ap…

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Castration-Resistant (CRPC) Prostate Cancer Trials on Trialify →